Strupp KUM Logo Box 1 und 2 einzeln current research text box

Strupp Ausschnitt 02Principal Investigator: Dr. Michael Strupp  

Disease: Menière’s disease

Research Description: Menière’s disease (MD) is a chronic inner ear condition, with symptoms including vertigo, dizziness, loss of balance, hearing loss, tinnitus and ear pressure. Although a number of therapeutic options have been proposed to treat MD, including a low salt diet, surgery and steroid injections into the inner ear, no FDA approved therapies for MD currently exist. In Europe, the anti-vertigo drug betahistine was approved to treat MD over 50 years ago, and betahistine is a commonly prescribed generic drug outside the US. However, its efficacy in treating MD has not yet been definitely shown. The research team has previously found that higher doses of betahistine can be more effective in reducing MD symptoms than lower doses, but patients must take a very large number of pills to achieve the higher dose levels. The team also discovered that combining betahistine with selegiline, a generic drug approved for Parkinson’s disease inhibits the enzyme that also metabolizes betahistine, leading to higher blood concentrations. Therefore, this drug combination may improve the clinical efficacy of betahistine even at lower doses. The team now proposes a clinical study to determine the efficacy of combining betahistine and selegiline in MD patients, potentially resulting in a new therapeutic approach not only for MD but also for other vestibular disorders.


CWR funding role: Primary funder

CWR funding parter: Becky and Lester Knight


Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Saturday the 28th. Copyright 2018 Cures Within Reach.